- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03560271
A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Study site 29
-
Birmingham, Alabama, United States, 35216
- Study Site 26
-
-
California
-
Chula Vista, California, United States, 91911
- Study site 27
-
La Mesa, California, United States, 91942
- Study site 28
-
Montclair, California, United States, 91763
- Study site 10
-
North Hollywood, California, United States, 91606
- Study site 23
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Study site 13
-
DeLand, Florida, United States, 32720
- Study site 19
-
Miami, Florida, United States, 33155
- Study site 14
-
Miami Beach, Florida, United States, 33140
- Study site 12
-
Orlando, Florida, United States, 32806
- Study site 15
-
Saint Petersburg, Florida, United States, 33711
- Study site 16
-
-
Georgia
-
Peachtree Corners, Georgia, United States, 30071
- Study site 21
-
Snellville, Georgia, United States, 30078
- Study site 17
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Study Site 20
-
-
Michigan
-
Caro, Michigan, United States, 48723
- Study site 30
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Study site 24
-
-
Ohio
-
Cleveland, Ohio, United States, 44142
- Study site 18
-
-
Texas
-
San Antonio, Texas, United States, 78220
- Study site 22
-
San Antonio, Texas, United States, 78249
- Study site 11
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females aged 18 or older.
- Subjects diagnosed with type 2 diabetes mellitus (DM) according to the American Diabetes Association (ADA) criteria.
- Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes mellitus for at least 2 months prior to randomization and who agree to stay on stable doses of anti-diabetes agents during the study.
- Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to randomization and during the 2-week screening period.
- Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening and a fasting plasma glucose less than 310 mg/dL.
- Subjects who can give written informed consent.
- Subjects who are willing and able to monitor their blood glucose concentrations with a home glucose monitor (before breakfast and 2 hours after dinner).
Female subjects must be either:
- Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 months before randomization, or
- Post-menopausal for at least 12 months prior to Screening, or
- If of childbearing potential and sexually active, must agree to use adequate contraception from Screening to completion of the study.
Exclusion Criteria:
- Subjects who have any significant DM-related end-organ damages.
- Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
Subjects who have any disease likely to limit life span and/or increase risks of interventions such as:
- Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid arteries requiring intervention by angioplasty or resection.
- Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry a good prognosis.
- Infectious disease: HIV positivity, active tuberculosis, or pneumonia.
Subjects with evidence of clinically significant cardiovascular or cerebrovascular disease, including (but not limited to):
- Hospitalization for the treatment of heart disease in the past 12 months.
- New York Heart Association Functional Class > 2.
- Left bundle branch block on ECG at Screening.
- Third degree atrioventricular block on ECG at Screening.
- Stroke or transient ischemic attack in the past 12 months.
- Subjects with uncontrolled hypertension with average systolic blood pressure of ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg at Screening and Baseline.
- Subjects with pulse rate ≥ 95 beats per minute at Screening and Baseline.
Subjects who have or had any of the following conditions related to gastrointestinal disease:
- Chronic hepatitis or cirrhosis.
- Episode of alcoholic hepatitis or pancreatitis.
- Inflammatory bowel disease or irritable bowel syndrome.
- Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months.
- Serum creatinine ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females.
- Hemoglobin ≤ 12 g/dL for males or ≤ 10 g/dL for females.
- Subjects who have chronic obstructive airway disease or asthma requiring daily inhaled corticosteroid therapy or home use oxygen.
Subjects who have any of the following conditions or behaviors likely to affect the conduct of the study:
- Weight loss of > 10% in the past 6 months.
- Unable to walk without assisted device.
- Major psychiatric disorder which would impede conduct of the research.
- Excessive alcohol intake (i.e., more than 2 drinks/day).
- Use of illicit drugs or drugs of abuse.
Subjects who take any of the following medications:
- Psychoactive agents such as monoamine oxidase inhibitors and antidepressants (e.g., lithium, Prozac, Zoloft, Serzone, Paxil, Effexor).
- Any insulin sensitizers (thiazolidinediones - TZDs) such as Avandia, Actos or Duvie, etc.
- Subjects with any other clinically significant and/or unexplained abnormalities that, in the opinion of the Investigator, could impact the subject's ability to fully participate in or complete the study.
- Female subjects who have a positive serum pregnancy test at Screening, plan a pregnancy during study period, or are breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose A
Cyclo-Z containing 23 mg zinc plus 6 mg CHP
|
Cyclo (His-Pro) and zinc
Other Names:
|
Experimental: Dose B
Cyclo-Z containing 23 mg zinc plus 15 mg CHP
|
Cyclo (His-Pro) and zinc
Other Names:
|
Placebo Comparator: Dose C
Placebo
|
Matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24
Time Frame: Day 1 to 24 weeks
|
Change in HbA1c from Day 1 to Week 24
|
Day 1 to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in HbA1c over time
Time Frame: Day 1 to 24 weeks
|
Change in HbA1c over 24 weeks
|
Day 1 to 24 weeks
|
Change from Baseline in fasting plasma glucose (FPG) levels over time
Time Frame: Day 1 to 24 weeks
|
Change in FPG levels over 24 weeks
|
Day 1 to 24 weeks
|
Change from Baseline in plasma insulin over time
Time Frame: Day 1 to 24 weeks
|
Change in plasma insulin over 24 weeks
|
Day 1 to 24 weeks
|
Proportion of subjects achieving HbA1c goal of < 7.0% at Week 24
Time Frame: Day 1 to 24 weeks
|
Percent of subjects who achieved HbA1c of <7% at Week 24
|
Day 1 to 24 weeks
|
Proportion of subjects achieving HbA1c goal of < 6.5% at Week 24
Time Frame: Day 1 to 24 weeks
|
Percent of subjects who achieved HbA1c of <6.5% at Week 24
|
Day 1 to 24 weeks
|
Proportion of subjects with decrease in HbA1c of ≥ 0.5% from Baseline at Week 24
Time Frame: Day 1 to 24 weeks
|
Percent of subjects who achieved HbA1c decrease at Week 24 of ≥ 0.5% from Day 1
|
Day 1 to 24 weeks
|
Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24
Time Frame: Day 1 to 24 weeks
|
Percent of subjects who achieved HbA1c decrease at Week 24 of ≥ 1.0% from Day 1
|
Day 1 to 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MiRa Huyghe, NovMetaPharma Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMP-CYZ-P2-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Cyclo-Z
-
VA Office of Research and DevelopmentTerminated
-
NovMetaPharma Co., Ltd.CompletedDiabetes Mellitus Type 2 in ObeseUnited States
-
University of California, DavisCompleted
-
Jürgen WeissUnknown
-
University of OxfordUnknownEbola Virus DiseaseUnited Kingdom
-
Zeria PharmaceuticalCompletedAdvanced Hepatocellular CarcinomaJapan
-
Everfront Biotech Co., Ltd.Active, not recruitingAmyotrophic Lateral SclerosisTaiwan
-
Zeria PharmaceuticalTerminated
-
Zeria PharmaceuticalCompletedPrimary Hypophosphatemic RicketsJapan
-
University of WashingtonCompletedHypertrophic Scarring After Burn InjuryUnited States